[The use of botulinum toxin type A in symptomatic therapy and medical rehabilitation of patients with multiple sclerosis].
E V KostenkoPublished in: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova (2023)
The review of the current state of the problem of symptomatic therapy and medical rehabilitation (MR) of patients with multiple sclerosis (MS) is presented. The search was conducted in the databases Medline, Web of Science, PubMed and Scopus. Information is given about the most common symptoms of MS, among which sensory and motor disorders, bladder dysfunction, and pain have the greatest impact on the quality of life of patients, their functioning and independence in everyday life. The clinical characteristics of spasticity syndrome in MS and its relationship with quality of life indicators are considered. The features of the use of botulinum therapy (BT) in MS are considered. A high level of effectiveness of the use of BT in the treatment of neurogenic hyperactivity of detrusor and neurogenic bladder (the level of persuasiveness of recommendation A) and spasticity (the level of persuasiveness of recommendation B) is shown. Symptomatic treatment of MS and MR with the use of multidisciplinary programs helps to reduce disability, improve the quality of life of patients. When choosing symptomatic treatment and MR methods, it is customary to focus on the needs of patients.
Keyphrases
- end stage renal disease
- spinal cord injury
- multiple sclerosis
- botulinum toxin
- mass spectrometry
- ejection fraction
- ms ms
- newly diagnosed
- chronic kidney disease
- peritoneal dialysis
- prognostic factors
- systematic review
- randomized controlled trial
- stem cells
- oxidative stress
- computed tomography
- neuropathic pain
- pain management
- big data
- urinary tract